Litcius/Paper detail

Total events and net clinical benefit of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: The COMPASS trial

Kelley R. Branch, Jeffrey L. Probstfield, Jackie Bosch, Deepak L. Bhatt, Aldo P. Maggioni, Eva Muehlhofer, Álvaro Avezum, Petr Widimský, Stuart J. Connolly, Quilong Yi, Olga Shestakovska, Salim Yusuf, John W. Eikelboom

2023American Heart Journal12 citationsDOI

Topics & Concepts

MedicineRivaroxabanAspirinCompassCoronary artery diseasePeripheralInternal medicineCardiologyArterial diseaseClinical trialVascular diseaseWarfarinAtrial fibrillationGeographyCartographyAntiplatelet Therapy and Cardiovascular DiseasesPeripheral Artery Disease ManagementAtrial Fibrillation Management and Outcomes
Total events and net clinical benefit of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: The COMPASS trial | Litcius